Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort

BACKGROUND: Protease inhibitors (PI) including boceprevir, telaprevir and simeprevir have revolutionised HCV genotype 1 treatment since their introduction. A number of pre-treatment resistance associated amino acid variants (RAVs) and polymorphisms have been associated with reduced response to treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shepherd, Samantha J., Abdelrahman, Tamer, MacLean, Alasdair R., Thomson, Emma C., Aitken, Celia, Gunson, Rory N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2015
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728298/
https://www.ncbi.nlm.nih.gov/pubmed/25766988
http://dx.doi.org/10.1016/j.jcv.2015.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728298/
https://www.ncbi.nlm.nih.gov/pubmed/25766988
http://dx.doi.org/10.1016/j.jcv.2015.02.005

Ejemplares similares